NCT00971295View on ClinicalTrials.gov

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

September 30, 2008

Conditions

Neuropathic Pain

Interventions

DRUG

Metformin

850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days

DRUG

Eslicarbazepine acetate

Trial Locations (1)

Unknown

Human Pharmacology Unit (UFH)Section of Clinical Research (SIC), Department of Research & Development (DID), BIAL - Portela & Cª, SA,, Mamede Do Coronado

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY

NCT00971295 - Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers | Biotech Hunter | Biotech Hunter